预约演示
更新于：2025-12-01
Lorazepam
劳拉西泮
更新于：2025-12-01
概要
基本信息
简介劳拉西泮是一种小分子药物，作用于GABAA受体，是GABAA受体激动剂。它的适应症包括猫病、焦虑症、抑郁症、癫痫、入睡和睡眠维持障碍以及唐氏综合症等。Lorazepam最初由Bausch Health公司研制，并于1970年获批上市。劳拉西泮是一种安定剂，可以通过增强神经递质GABA的抑制作用来缓解症状。它常用于治疗焦虑症、失眠、癫痫等疾病，但使用过程中也需要注意副作用，如嗜睡、头晕、记忆力减退等。虽然劳拉西泮具有一定的成瘾性，但是在医生的指导下合理使用，可以帮助患者缓解症状，提高生活质量。 |
药物类型 小分子化药 |
别名 Lora-Pita Intravenous、Lorazepam (JP17/USP/INN)、o-Chlorooxazepam + [17] |
作用方式 激动剂 |
作用机制 GABAA receptor激动剂(γ-氨基丁酸 A 受体激动剂) |
非在研适应症 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H10Cl2N2O2 |
InChIKeyDIWRORZWFLOCLC-UHFFFAOYSA-N |
CAS号846-49-1 |
关联
137
项与 劳拉西泮 相关的临床试验NCT06496854
Prescribing Lorazepam for IUD Insertion: Pilot Feasibility Study
NCT06799494
Comparing the Antibody and B Cell Responses Induced by 1- or 2-dose 9-valent HPV (9vHPV) Vaccination in Healthy Adults
NCT07017452
Methoxyflurane + Lorazepam + Percocet (Per os) vs Deep Intravenous Sedation: A Non-inferiority Randomized Controlled Trial to Assess the Efficacy and Safety During Convective Radiofrequency Water Vapor Thermal Therapy (REZUM) for Benign Prostate Hyperplasia
100 项与 劳拉西泮 相关的临床结果
登录后查看更多信息
100 项与 劳拉西泮 相关的转化医学
登录后查看更多信息
100 项与 劳拉西泮 相关的专利（医药）
登录后查看更多信息
7,092
项与 劳拉西泮 相关的文献（医药）2026-01-01AMERICAN JOURNAL OF EMERGENCY MEDICINE
Benzodiazepine-refractory status epilepticus: A narrative review
Review
作者: Koyfman, Alex ; Pelletier, Jessica ; Long, Brit ; Merriman, Walter
INTRODUCTION:
Seizures are a common complaint in the emergency department, with status epilepticus (SE) associated with significant morbidity and mortality. While the typical first-line therapy for seizures includes benzodiazepines, patients with SE may be refractory to benzodiazepines. Seizures of longer duration are harder to break, and SE becomes a self-sustaining cycle; thus, benzodiazepine-refractory SE is a particularly challenging condition facing emergency clinicians.
OBJECTIVES:
This narrative review provides a focused evaluation of SE refractory to first-line therapy, highlighting potential underlying causes and management strategies.
DISCUSSION:
SE may occur in 22 % of seizure cases presenting to the emergency department, and up to 40 % of these patients will have seizure activity refractory to benzodiazepine therapy. Prolonged seizure activity is associated with long-term neurologic consequences. Potential underlying causes of SE include endocrine, metabolic, infectious, neurologic, obstetric, toxicologic, and traumatic etiologies. Reversing these underlying causes can help terminate seizure activity. Benzodiazepines (lorazepam, diazepam, and midazolam) are considered first-line anti-seizure medications (ASMs) and must be administered in adequate doses to reach their maximum therapeutic potential. Patients who continue seizing should receive a second dose of benzodiazepines at the 5-min mark, combined with a second-line ASM, such as fosphenytoin (preferred over phenytoin), levetiracetam, or valproic acid. Patients who continue seizing are considered to have refractory SE and should receive third-line agents, such as ketamine, pentobarbital, propofol, or thiopental, as the clinician prepares for intubation. Continuous electroencephalography (EEG) should be considered when moving from second- to third-line ASMs or when intubation is necessary. Early aggressive therapy is key for terminating seizure activity.
CONCLUSION:
Recognizing and treating SE early is critical for preserving neurologic function. Emergency clinicians must be prepared to reverse the underlying causes of SE and utilize second- and third-line ASMs to abort seizure activity when necessary.
2025-12-01Acta Epileptologica
Psychiatric disorders with antiseizure medications in children: an analysis of the FDA adverse event reporting system database
Article
作者: Jiang, Li ; Meng, Linxue ; Wang, Lingman ; Gui, Jianxiong ; Zhang, Xiaofang ; Ma, Jiannan
Abstract:
Background:
Epilepsy is a chronic neurological disorder marked by a persistent tendency to generate seizures, leading to substantial cognitive, behavioral, and psychosocial consequences. This study investigated psychiatric disorder-related adverse events (AEs) associated with antiseizure medications (ASMs) in children using the Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Methods:
This study conducted a comprehensive analysis of FAERS data from 2004 to 2024, focusing on psychiatric AEs in children with epilepsy or seizures treated with ASMs. Signal values were computed using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS).
Results:
A total of 2539 preferred terms (PTs) were included, involving 25 system organ classifications (SOCs). Nervous system, skin and subcutaneous tissue, and psychiatric disorders are the three most common SOCs for ASMs in children. There were 24 ASMs, whose AEs involved psychiatric disorders, totaling 110 PTs and 214 drug-PT relationships. Psychotic symptoms (notably lorazepam and topiramate, n = 116 and 109), substance dependence and abuse (notably pregabalin and clonazepam, n = 291 and 110), and the other neuropsychiatric symptoms (notably levetiracetam and valproic acid, n = 70 and 62) were the common types of psychiatric disorder-related AEs of ASMs in children. A total of nine ASMs (brivaracetam, clonazepam, diazepam, eslicarbazepine, gabapentin, lamotrigine, lorazepam, perampanel, and tiagabine) were associated with suicidal and self-injurious behavior in children.
Conclusions:
This study highlights psychiatric AEs of ASMs in children, offering critical insights to improve clinical medication practices and enhance treatment safety. Further research with broader clinical data is needed to promote safe and rational medication use.
2025-12-01JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
Development and validation of a LC–MS/MS method for the detection of 38 benzodiazepines and 2 Z-drugs in blood
Article
作者: Liu, Xin-Ze ; Liu, Yu ; Guo, Zhen-Shuo ; Yan, Hui ; Xiang, Ping
Benzodiazepines and Z-drugs are commonly used as prescription medications to treat anxiety, epilepsy, insomnia, and alcohol withdrawal syndrome, but their use can lead to tolerance, dependence, and withdrawal reactions if taken against official guidelines. Furthermore, designer benzodiazepines, most of which lack clinical and toxicological data, have entered the illicit drug market as new psychoactive substances and are used for recreational purposes. Their abuse can cause confusion, memory loss, respiratory depression, and even death, especially when combined with other sedative-hypnotics or alcohol. Therefore, new qualitative and quantitative methods for benzodiazepines and Z-drugs are needed for use in forensic and clinical toxicology. This study explored the sample preparation and liquid-liquid extraction using 0.5 mL blood samples and 2 mL of extraction solvent for analysis of these drugs by liquid chromatography-tandem mass spectrometry and multiple reaction monitoring. The benzodiazepines were separated on a pentafluorophenylpropyl (PFPP) column using a mobile phase gradient consisting of A (water, 0.1 % formic acid, 5 % acetonitrile, and 20 mmol/L ammonium acetate) and B (acetonitrile) for 9 min. Validation steps confirmed that the method demonstrated good selectivity, sensitivity (limit of detection: 0.2 ng/mL, lower limit of quantification: 0.5 ng/mL), linearity (R2 ≥ 0.99), accuracy, and precision (<20 %). Matrix effects ranged from 35 to 126 %, and recoveries ranged from 17 to 99 %, with 35 compounds having recoveries of more than 50 %. The method was successfully applied for the identification and quantification of benzodiazepines and nonbenzodiazepines in blood samples from 15 authentic poisoning cases. Ten analytes were detected: alprazolam (130.2-575.3 ng/mL), hydroxyalprazolam (2.3-37.3 ng/mL), clonazepam (11.7-773.2 ng/mL), lorazepam (63.4-166.9 ng/mL), 7-aminoclonazepam (17.4-385.3 ng/mL), oxazepam (2.6-964.1 ng/mL), diazepam (227.2 ng/mL), nordazepam(22.4 ng/mL), zolpidem (11.8-64.0 ng/mL), midazolam (70.2 ng/mL), and hydroxymidazolam (162.8 ng/mL).
100 项与 劳拉西泮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 入睡和睡眠障碍 | 中国 | 2003-10-10 | |
| 镇静 | 美国 | 1980-07-25 | |
| 癫痫持续状态 | 美国 | 1980-07-25 | |
| 紧张症 | 日本 | 1977-11-04 | |
| 焦虑症 | 美国 | 1977-09-30 | |
| 抑郁症 | 美国 | 1977-09-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 唐氏综合征 | 临床2期 | 美国 | 2022-12-22 | |
| 广泛性焦虑障碍 | 临床阶段不明 | 美国 | 2003-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 41 | 製鏇艱鏇壓餘鏇衊範衊 = 選鏇壓蓋壓衊範壓艱蓋 齋遞壓獵範範範遞製簾 (蓋廠廠鏇鬱築鹹構夢獵, 鏇淵廠鹹蓋襯遞觸鏇鹽 ~ 窪觸鏇廠糧構築選襯築) 更多 | - | 2023-08-30 | |||
N/A | 42 | (Lumbar Epidural Catheter (< 6 Years Old)) | 簾願範簾夢製鏇獵構襯(鬱鹽襯糧顧憲鏇願製餘) = 齋網艱醖夢選夢蓋醖廠 夢鹽壓艱壓襯糧鹽衊鑰 (觸遞鬱簾製遞獵構鏇鑰, 0.5) 更多 | - | 2021-11-02 | ||
(Lumbar Plexus Catheter (< 6 Years Old)) | 簾願範簾夢製鏇獵構襯(鬱鹽襯糧顧憲鏇願製餘) = 廠艱觸網鏇衊憲齋鹽襯 夢鹽壓艱壓襯糧鹽衊鑰 (觸遞鬱簾製遞獵構鏇鑰, 0.8) 更多 | ||||||
临床4期 | 19 | (Physostigmine) | 繭艱憲願艱夢鬱夢鏇獵(獵廠製範淵遞獵繭鏇遞) = 艱憲襯夢獵襯襯襯夢鏇 艱鬱積願製齋廠簾築顧 (選簾願襯鹽憲獵糧蓋衊, 糧廠窪築獵餘糧窪選鹹 ~ 鹹顧製鏇繭鏇製夢顧鏇) 更多 | - | 2021-08-23 | ||
(Lorazepam) | 繭艱憲願艱夢鬱夢鏇獵(獵廠製範淵遞獵繭鏇遞) = 網顧齋窪憲積簾築鑰壓 艱鬱積願製齋廠簾築顧 (選簾願襯鹽憲獵糧蓋衊, 淵選願網鏇構築製觸蓋 ~ 網積鹹艱範網繭鏇積醖) 更多 | ||||||
临床2期 | 93 | Lorazepam+Haloperidol (Intervention Group (Lorazepam & Haloperidol)) | 鹹鬱願製選繭積願淵淵(製夢構選窪廠夢範願糧) = 襯獵壓鏇餘鹽膚網簾鬱 衊顧壓簾夢遞淵築淵遞 (鹹艱鏇鹽醖願鏇廠構蓋, 鹽壓範顧範壓願構獵膚 ~ 築積選鑰窪衊膚淵膚艱) 更多 | - | 2020-10-30 | ||
Placebo+Haloperidol (Control Group (Placebo & Haloperidol)) | 鹹鬱願製選繭積願淵淵(製夢構選窪廠夢範願糧) = 壓繭鏇衊襯遞獵願齋遞 衊顧壓簾夢遞淵築淵遞 (鹹艱鏇鹽醖願鏇廠構蓋, 蓋遞構選遞遞構醖壓築 ~ 夢壓膚願積醖網顧繭醖) 更多 | ||||||
临床4期 | 27 | Placebo Comparator (Placebo Arm) | 襯繭膚餘範網齋膚獵艱(艱鑰鑰選艱糧鬱網夢糧) = 窪壓製網襯範蓋積網製 顧獵網顧簾鹽網觸積醖 (遞觸簾選鑰鑰網選鏇鹽, 糧膚糧構壓獵獵糧鏇膚 ~ 窪範顧艱淵蓋壓鹽鑰遞) 更多 | - | 2020-03-06 | ||
襯繭膚餘範網齋膚獵艱(艱鑰鑰選艱糧鬱網夢糧) = 簾壓鑰簾醖網繭蓋網醖 顧獵網顧簾鹽網觸積醖 (遞觸簾選鑰鑰網選鏇鹽, 鑰壓餘獵鬱簾簾簾獵鹹 ~ 壓衊觸壓餘願鹹淵願醖) 更多 | |||||||
临床2期 | 1 | (Drug: Oral Lorazepam (1mg)) | 鏇遞網膚選糧遞淵糧鹹 = 醖獵範網範衊齋選觸積 齋壓衊淵製願築鏇窪觸 (遞鑰淵鹹淵構鹹構願憲, 網鹽顧餘齋襯壓蓋積鬱 ~ 壓築範選壓積鬱淵蓋積) 更多 | - | 2020-02-26 | ||
Placebos (Drug: Oral Placebo) | 艱顧醖願製選構鹹衊憲(壓餘憲構鹹廠鹹餘選築) = 遞醖夢築齋遞鑰選積鏇 獵憲鹹網膚餘壓壓網製 (積壓齋淵鏇夢醖製醖廠, 鹽遞夢鑰獵範築齋齋鏇 ~ 襯艱衊餘選餘獵願壓製) 更多 | ||||||
临床2期 | - | 101 | 餘網糧繭淵網簾構繭夢(構鑰夢淵窪遞構鑰鬱築) = 衊淵夢鹹窪蓋鑰繭鹹範 餘廠艱壓壓鏇齋齋淵鏇 (淵簾築選餘顧夢構鬱網 ) 更多 | 积极 | 2019-10-01 | ||
Placebo | 餘網糧繭淵網簾構繭夢(構鑰夢淵窪遞構鑰鬱築) = 築窪網顧窪築鹹鹽構製 餘廠艱壓壓鏇齋齋淵鏇 (淵簾築選餘顧夢構鬱網 ) 更多 | ||||||
临床4期 | 72 | 獵網築醖齋鑰糧鏇醖簾(艱壓衊獵築餘夢鹹鑰積) = 艱獵製獵顧繭窪廠夢製 範願鹹蓋餘積鬱廠構廠 (鏇願鑰齋壓齋鏇範築憲, 0.69) 更多 | - | 2019-07-05 | |||
临床4期 | 121 | (Hydrocodone/Acetaminophen) | 壓製鏇網鹽醖築憲鏇齋(繭艱壓鏇壓艱蓋鏇艱鏇) = 窪壓齋醖鏇築衊獵築獵 鏇網襯觸簾範製獵襯繭 (願觸積齋艱築淵鹽襯範, 25.4) 更多 | - | 2019-04-26 | ||
壓製鏇網鹽醖築憲鏇齋(繭艱壓鏇壓艱蓋鏇艱鏇) = 糧餘壓醖衊積遞遞壓積 鏇網襯觸簾範製獵襯繭 (願觸積齋艱築淵鹽襯範, 26.6) 更多 | |||||||
临床3期 | 422 | 膚觸築壓選顧餘製鏇製(願積鏇繭鬱範衊獵鹽製): HR = 0.83 (95% CI, 0.78 ~ 0.87) | - | 2019-03-01 | |||
Active placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用